Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. (NTRA) director and co-founder Sheena Jonathan reported sales of 18,064 common shares by Caraluna 1 Trust and Caraluna 2 Trust on September 23, 2026, across 12 transactions. The sales were made under a Rule 10b5-1 trading plan adopted on June 11, 2026. The trusts held the shares for their beneficiaries, and Jonathan disclaimed beneficial ownership.
Natera, Inc. director Jonathan Sheena reported a proposed sale of 21,064 common shares through Charles Schwab & Co., Inc., with an aggregate market value of $8,163,402 and an approximate sale date of September 23, 2026. The notice also lists nine common-share sales during the preceding three months, ranging individually from 109 to 9,150 shares.
Natera, Inc. (NTRA) reported that Solomon Moshkevich, President, Clinical Diagnostics, made a bona fide gift of 945 shares of Common Stock on September 16, 2026 as a charitable contribution. Following this disposition, he directly holds 109,914 shares of Natera common stock, and no Rule 10b5-1 plan is reported.
Natera, Inc. (NTRA) director and co-founder Sheena Jonathan reported open-market sales of a total of 9,150 shares of common stock on September 15–16, 2026, at weighted-average prices ranging from about $348.03 to $356.87 per share, as separate sale tranches.
The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025. Jonathan is also reported as having indirect positions of 18,032 shares held by each of Caraluna 1 Trust and Caraluna 2 Trust, with beneficial ownership over those securities disclaimed.
Natera, Inc. (NTRA) reported that Executive Chairman Matthew Rabinowitz disclosed open-market sales of a total of 102,000 sharesweighted average prices$327.50 to $351.272,000 sharespre-established Rule 10b5-1 trading plans
Natera, Inc. (NTRA) is named as the issuer in a notice that the TINKERBELLE II TR U/A DTD 10/22/2021, with trustee Sharon Minto, may sell 2,000 shares of Natera common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $700,014.60. The notice also lists recent Rule 10b5-1 and other sales of Natera common stock over the prior three months by Matthew Rabinowitz and the same trust.
Natera, Inc. (NTRA) reported that executive chairman and director Matthew Rabinowitz sold a total of 50,000 shares of Natera common stock on September 11, 2026 under a pre-arranged Rule 10b5-1 trading plan. The sales occurred in multiple open-market transactions at weighted average prices within several stated price ranges.
Natera, Inc. (NTRA) received a Form 144 notice from stockholder Matthew Rabinowitz covering a proposed sale of 200,000 shares of common stock, to be handled through Morgan Stanley Smith Barney LLC’s Executive Financial Services desk on Nasdaq. The shares were obtained through the exercise of stock options between May 8, 2024 and November 11, 2024.
The notice also lists prior sales of Natera common stock during the past three months by Matthew Rabinowitz and the TINKERBELLE II Trust, including two 10b5-1 plan sales of 50,000 shares each on June 12, 2026 and June 15, 2026, plus several smaller transactions.
Natera, Inc. (NTRA) reported that Solomon Moshkevich, its President, Clinical Diagnostics, sold a total of 18,160 shares of common stock in early September 2026. On September 1, 2026, he sold 3,000 shares in multiple transactions pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024, at weighted average prices between $319.29 and $322.11 per share. On September 2, 2026, he sold 15,160 shares at $326.89 per share to satisfy tax withholding and remittance obligations related to vesting RSUs, under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c).
Natera, Inc. (NTRA) reported that Chief Executive Officer and President Steven Leonard Chapman sold 1,698 shares of common stock on September 1, 2026 in an open-market or private transaction at a price of $320.99 per share. After this sale, he directly holds 98,199 shares of Natera common stock. The sale was effected under a Rule 10b5-1 trading plan adopted on December 11, 2023 and amended on December 2, 2024 and March 5, 2026.